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Extracellular vesicles (EV), structures surrounded by a biological membrane, transport
biologically active molecules, and represent a recently identified way of intercellular
communication. Colorectal cancer (CRC), one of the most common cancer types in
the Western countries, is composed of both tumor and stromal cells and the amount of
stromal fibroblasts negatively correlates with patient survival. Here we show that normal
colon fibroblasts (NCF) release EVs with a characteristic miRNA cargo profile when
stimulated with TGFβ, one of the most important activating factors of fibroblasts, without
a significant increase in the amount of secreted EVs. Importantly, fibroblast-derived EVs
induce cell proliferation in epidermal growth factor (EGF)-dependent patient-derived
organoids, one of the best current systems to model the intra-tumoral heterogeneity
of human cancers. In contrast, fibroblast-derived EVs have no effect in 3D models
where EGF is dispensible. This EV-induced cell proliferation did not depend on whether
NCFs or cancer-associated fibroblasts were studied or on the pre-activation by TGFβ,
suggesting that TGFβ-induced sorting of specific miRNAs into EVs does not play a
major role in enhancing CRC proliferation. Mechanistically, we provide evidence that
amphiregulin, transported by EVs, is a major factor in inducing CRC cell proliferation. We
found that neutralization of EV-bound amphiregulin blocked the effects of the fibroblast-
derived EVs. Collectively, our data suggest a novel mechanism for fibroblast-induced
CRC cell proliferation, coupled to EV-associated amphiregulin.
Keywords: organoid, fibroblast, amphiregulin, exosomes, colorectal cancer, TGFβ
INTRODUCTION
Extracellular vesicles (EV) are membrane-surrounded structures released by virtually all cell types.
They transport biologically active molecules (such as nucleic acids, lipids and proteins) from
the releasing to the target cells, thus, participating in the recently identified way of intercellular
communication (Tkach et al., 2018). Since EVs transport their cargo in a protected way in the
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tissues and body fluids, furthermore, molecules specific for
the releasing tumor cells are represented in them at a high
concentration, they provide a promising tool for early cancer
diagnostics. EVs form a heterogeneous group of vesicles
according to both their size and cellular origin (Thery et al.,
2018). Small EVs (sEVs, 35–150 nm), e.g., exosomes are released
from the multivesicular bodies of the endosomal-lysosomal
system, while medium sized EVs (mEVs, 100–1,000 nm) are
commonly shed from the plasma membrane by a budding
mechanism (Thery et al., 2018). There are also large EVs (e.g.,
apoptotic bodies, >1,000 nm) that carry not only molecules but
organelles as well (Mathieu et al., 2019). Despite the emerging
evidence that EVs contribute to tumorigenesis and play a critical
role in the communication among stromal and cancer cells
(Maia et al., 2018), changes in their release intensity, cargo in
different fibroblast populations, and mechanism of their action
on colorectal cancer (CRC) cells is by far not yet understood.
Colorectal cancer is among the most frequent cancer types
in the developed world. In more than 80% of CRC patients,
mutation in the APC gene is an initializing genetic change,
leading to the continuous and ligand-independent activation of
the Wnt pathway (Kinzler and Vogelstein, 1996). In addition,
the oncogenic activation of KRAS leads to the independency
of the adenoma cells from external epidermal growth factor
(EGF) activity. This adenoma stage can then progress to
carcinomas with the accumulation of other genetic changes,
such as inactivation of TP53 and the TGFβ signaling pathway.
The recently developed organoid systems represent relevant
in vitro methods to study human cancers (Bleijs et al., 2019).
Importantly, patient-derived cancer organoids maintain the
cellular heterogeneity of the original tissue when cultured under
well-defined conditions and they provide a valuable tool to
monitor tumor progression in human samples as well (Drost
et al., 2015; Matano et al., 2015; Bolck et al., 2019).
The accumulation of cancer-associated fibroblasts (CAF), an
important and abundant cell type in the stroma, results in a
worse patient survival in CRC (Calon et al., 2015). CAFs are
often identified by the expression of α-smooth muscle actin
(αSMA) or fibroblast−activating protein (FAP). Importantly,
TGFβ plays a central role in the activation of fibroblasts in CRC
and it induces a specific gene expression program, including the
induction of HBEGF, IL-6, and IL-11 expression. IL-11 initializes
CRC invasion and metastasis via activating the STAT signaling
pathway (Calon et al., 2012). The peri-tumoral fibroblasts (PTF),
isolated from the normal colon near to the tumor tissue, are often
used as the unactivated control cells for CAFs (Herrera et al.,
2018). However, a recent publication comparing the expression
profiles of PTFs and CAFs found a low level of difference
between the corresponding pairs. In this study αSMA, generally
considered as a marker of the activated fibroblasts, was present in
PTFs as well (Berdiel-Acer et al., 2014).
Interestingly, CAFs critically contribute to the cellular
heterogeneity of CRC and to the acquision of the aggressive
cancer stem cell phenotype (Vermeulen et al., 2010; Essex et al.,
2019). In addition, we found that intestinal fibroblast-derived
EVs carry amphiregulin (AREG), a member of the EGF ligand
family, and EVs have a central role in shaping the intestinal stem
cell niche (Oszvald et al., 2020). However, the role of EVs as
conveyors of messages in the stroma-CRC cell communication
is not well understood.
MATERIALS AND METHODS
Cell Culture
SW1222 CRC cells were obtained from ECACC (European
Collection of Authenticated Cell Cultures) and they
were cultured in DMEM containing 4,500 g/L glucose
(Gibco), 10% FBS (Biosera), glutamine (Sigma), and 1×
penicillin/streptomycin (Gibco). Human colon fibroblasts
(American Tissue Culture Collection, ATCC-1459) (NCF)
were cultured in fibroblast medium containing DMEM
high glucose (containing 4,500 g/L glucose, Gibco), 10%
FBS, glutamine and Penicillin/Streptomycin. Cells were
washed with phosphate buffered saline (PBS) three times and
cultured in serum-free medium or in CRC medium for 2 days
before collecting/measuring EVs. CRC medium contained
advanced DMEM/F12, 1× N2 and 1× B27 supplement
(Gibco), 1 mM N-Acetyl-Cysteine, 10 mM HEPES (Sigma),
penicillin/streptomycin, antibiotic/antimycotic mix (Gibco),
and glutamine. Cell cultures were tested for mycoplasma with
Hoechst staining and they were negative in our studies. We only
used cells with <p9 passage numbers after obtaining from ATCC
or ECACC. Cell number was determined in a Burker chamber.
In some experiments cells were activated with 10 ng/mL TGFβ1
(Peprotech) for 4 days (Calon et al., 2012).
Isolation of Human Colon Fibroblasts
(PTF and CAF)
The Ethics Committee of the Medical Research Council
of Hungary (ETT-TUKEB, No. 51323-4/2015/EKU) approved
all experiments with human samples and informed consent
was obtained from the patients. Samples were collected at
the Department of Oncosurgery, Uzsoki Hospital, Budapest,
Hungary. Patient data are shown in Supplementary Tables S1,
S2. Tumor and normal colon tissue dissected at a distance
>5 cm from the tumor were isolated and cut into small pieces
(<0.5 cm) in PBS. After extensive washing with PBS three times,
tissue pieces were incubated in a digestive mix [DMEM high
glucose with 20% FBS, 75 U/mL collagenase type IX (Sigma),
and 125 µg/mL dispase type II (Invitrogen, Carlsbad, CA, United
States)] for 2 h at 37◦C with extensive shaking. After removal
of tissue pieces, single cells were then centrifuged at 300 g for
5 min, washed twice in PBS and cultured in tissue culture plates
(Eppendorf) in fibroblast medium containing 15% FBS.
Wound Healing Assay
Normal colon fibroblasts, PTFs or CRC-Fs were cultured in the
wells of 24-well plates until confluence. A scratch was created
with a 200 µL pipette tip. Cells were washed with PBS to remove
cell debris and they were cultured in 500 µL medium (DMEM
high glucose with 2.5% EV-free FBS, antibiotic/antimycotic mix,
and glutamine). In some experiments, cells were pre-treated with
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TGFβ (10 ng/mL, 4 days). Images were taken at 0, 16, and 24 h
(Nikon Diaphot microscope) and the areas without cells were
evaluated by the ImageJ software. Data are presented as relative
percentage compared to the wound size at the starting time point.
For determining the effect of TGFβ, this relative percentage was
compared to the control value.
Detection of SA-β-Galactosidase Activity
Cells were cultured in chamber slides (Falcon), they were fixed
with 4% paraformaldehyde (PFA) for 5 min and then washed with
water. Samples were incubated in staining solution to detect the
enzymatic activity according to (Debacq-Chainiaux et al., 2009)
at 37◦C in the dark without CO2. The reaction was stopped by
changing the solution to water after 8 h.
Human Colon Organoid Cultures
Tumor samples from CRC patients were processed according to
previously published protocols (Sato et al., 2011; van de Wetering
et al., 2015). The small cell clusters were isolated by centrifugation
at 300 g for 2 min and they were embedded into Matrigel
(Corning). In addition, we used patient-derived organoid lines
previously established in our laboratory (Szvicsek et al., 2019).
Organoids were cultured in CRC medium supplemented with
500 nM A83-01 (Sigma), 10 µM SB202190-Monohydrochloride
(Sigma), and 50 ng/mL EGF. Furthermore, the Rho kinase
inhibitor Y27632 (Sigma) was added for 2 days after splitting.
Organoids were removed from Matrigel in every 5–6 days
mechanically, they were centrifuged at 300 g for 5 min
and then disrupted by pipetting and digesting with TrypLE
(Thermo Fisher, Waltham, MA, United States) for 3–5 min.
Cell clusters were then washed and embedded into Matrigel
again. Clinical data of the CRC patients and characterization of
CRC organoids #1–3 have been published (Szvicsek et al., 2019;
Supplementary Table S1).
EV Isolation
Fibroblasts were cultured in CRC medium for 4 days with
or without 10 ng/mL TGFβ1 (Peprotech) and medium was
collected, serially centrifuged at 300 g for 5 min, 2,000 g for
20 min, and 12,500 g for 20 min to remove cells, cell fragments
and large EVs. Samples were then ultracentrifuged (UC) at
100,000 g for 70 min at 4◦C, the EV-containing pellet was
resuspended in PBS and UC again. The EV containing pellets
were then resuspended in PBS and they were used for functional
experiments or they were bound to latex beads (see section
“Functional studies with EVs”).
Nanoparticle Tracking Analysis (NTA)
Fibroblasts were cultured in FBS-free medium and the
experiments were carried out in the same standard conditions
(6-well plate, 100,000 cells/well, and 1.5 mL medium). Fibroblast
supernatants were harvested after 2 days, 0.5 mL supernatants
were serially centrifuged at 300 g for 5 min, 2,000 g for 20 min,
and 12,500 g for 20 min. After centrifugation, 100 µL supernatant
was diluted to 1 mL in PBS and particle size distribution and
concentrations were measured on a ZetaView Z- Nanoparticle
Tracking Analysis (NTA) instrument (Particle Metrix). For
each measurement, 11 cell positions were scanned at 25◦C.
The following camera settings were used: auto expose, gain:
28.8, offset: 0, shutter: 100, and sensitivity: 80. The videos were
analyzed with a minimum area of 5, maximum area of 1000
and a minimum brightness of 20 by the ZetaView Analyze
software 8.05.10.
Functional Studies With EVs
Ten µl (2.5 × 107) EVs were added to each well with CRC
organoids (20 µL Matrigel and 200 µL medium, 48-well tissue
culture plates, Eppendorf). In some experiments, EVs were
incubated with 10 µg/mL neutralizing anti-AREG antibody or
control goat IgG (see Supplementary Information) for 1 h
in 20 µL medium before applying them to organoids. When
indicated, organoids were pre-incubated with the EGF receptor
inhibitor gefitinib (5 µM, Tocris) 30 min before applying EVs and
they were further cultured in the presence of the inhibitor.
Semi-Quantitative Analysis of EVs by
Anti-CD63 or Anti-CD81-Coated Beads
Conditioned media from fibroblasts, harvested after 2 days, were
centrifuged at 300 g for 5 min and 2,000 g for 20 min. EVs
were then bound to beads coated with anti-CD63 (Thermo
Fisher, 10606D) or anti-CD81 (Thermo Fisher, 10616D). Before
incubating with the samples, beads had been blocked with 0.1%
BSA (Sigma) for 30 min at room temperature. 20 µL and 6 µL
of the anti-CD63 or anti-CD81-coated beads were added to
200 µL supernatant, respectively. Beads were rotated overnight
at 4◦C, they were then magnetically separated, washed with PBS
three times and they were labeled with FITC-anti-CD81, or PE-
anti-CD63. The proportion of positive beads was detected by
flow cytometry (FACSCalibur) and they were normalized to cell
number (to 100,000 and 300,000 cells in case of CD63 and
CD81-coated beads, respectively).
Detection of AREG on EVs
EVs were separated from the FBS-free 2 days conditioned media
of NCF or CAF cultures [5 × 105 cells were grown in a
10 cm cell culture plate (Eppendorf)]. EV-containing pellets were
resuspened in 500 µL PBS, they were incubated overnight at 4◦C
with 1 µL latex bead (Thermo Fisher # A37478, 3.9 g/100 mL),
and blocked with 1% BSA (Sigma). Beads were then washed three
times with PBS, they were divided into two parts and labeled with
anti-CD63 PE or anti-AREG for 2 h at 4◦C in 1% PBS. Anti-
goat Alexa 488 was applied as secondary antibody for 1 h at 4◦C.
Samples were measured on a FACSCalibur (BD Biosciences, San
Jose, CA, United States).
Immunocytochemistry
Cells were fixed in 4% PFA for 20 min. They were then
blocked and permeabilized in blocking buffer (PBS with 0.1%
BSA, 5% FBS, and 0.1% Triton X–100). After washing with
blocking buffer, cells were incubated with primary antibodies
at 4◦C overnight and then with secondary antibodies for 2 h
at room temperature. The incubation steps were carried out in
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blocking buffer. After covering samples with ProLong Diamond
antifade mountant countaining DAPI (Thermo Fisher, Waltham,
MA, United States), they were analyzed with a Zeiss LSM800
confocal microscope.
Whole-Mount Immunostaining
Colorectal cancer organoids were cultured in 8-well chamber
slides (BD Biosciences, San Jose, CA, United States), fixed
in 4% PFA for 30 min and washed with PBS. Blocking and
permeabilization were carried out in whole-mount blocking
buffer (WMBB, containing 5% FBS, 0.2% BSA, and 0.3% Triton
X–100 in PBS) for 30 min. Samples were incubated with
primary antibodies at 4◦C overnight in WMBB. After washing
in PBS + 0.3% Triton X–100 + 4% NaCl, labeled secondary
antibodies were added overnight at 4◦C. The organoids were then
mounted with ProLong Diamond antifade mountant countaining
DAPI (Thermo Fisher, Waltham, MA, United States) and
analyzed with a Zeiss LSM800 confocal microscope. Images were
evaluated by the ImageJ software. The antibodies used are listed
in Supplementary Table S3.
Transmission Electron Microscopy
The EV-containing pellet after UC and washing with PBS was
resuspended in 20 µl PBS and a 2 µL droplet was dried on a
300 mesh grid (Electron Microscopy Sciences, United States).
Fixing of EVs was carried out with 4% glutaraldehyde for 10 min
and the grid was washed with water three times. EVs were
treated with 2% phosphotungstic acid, they were dried at RT
and images were captured with a MORGAGNI 268D (FEI,
Netherlands) instrument.
RNA Isolation and mRNA Measurements
From Cells
RNA was isolated with the RNEasy Micro Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol in 15 µL
water. We measured RNA concentration with a NanoDrop
instrument. Half µg RNA (in 20 µL final volume) was reverse
transcribed with the SensiFASTTM cDNA Synthesis Kit (Bioline,
London, United Kingdom) and quantitative PCR reactions were
carried out using the SYBRGreen method with the SensiFASTTM
SYBR R© Hi-ROX Kit (Bioline, London, United Kingdom). We
used an ABI 7900HT Fast real-time PCR instrument in 384-well
format in 5 µL volume. Results were evaluated with the following
protocol: relative expression level = 2−1Ct , where 1Ct = Ct (gene
of interest) – Ct (housekeeping gene). The primers are listed in
Supplementary Table S4.
TaqMan Low Density miRNA Array
Normal colon fibroblasts were cultured with our without
10 ng/ml TGFβ (6-well plate, 100,000 cells/well, and 1.5 mL
medium). Fibroblast supernatants were harvested after 4 days,
serially centrifuged at 300 g for 5 min, 2,000 g for 20 min, 12,500 g
for 20 min, and the particle concentration was determined with
NTA. Sample volumes with 5× 108 particles were supplemented
with medium to 1 mL, EVs were isolated with anti-CD63 (40 µL),
and anti-CD81 (12 µL)-coated beads O/N, they were washed 5
times with PBS and EVs were lyzed in Qiazol (Qiagen, Hilden,
Germany). Total RNA with small RNAs was isolated with the
miRNeasy Micro Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions in 15 µL water. 2 µL total RNA was
reverse transcribed with Megaplex RT primers, the samples were
amplified with Megaplex PreAmp Primers and then TaqManTM
Array Human MicroRNA A Cards v2.0 (all from Thermo
Fisher, Waltham, MA, United States) were used according to the
manufacturer’s protocol. Array cards were measured with an ABI
7900HT instrument and Ct < 40 was regarded as miRNA present
in the sample. We then selected miRNAs that were absent in
all the three controls and present in the TGFβ-treated samples
(n = 3). As background measurements, samples isolated from
cell-free cultures were applied (n = 2).
Statistical Analysis
Kruskal–Wallis with Dunn post hoc test, Mann–Whitney U-test
or Student’s paired or unpaired t-tests were used with ∗p < 0.05,
∗∗p < 0.01, and ∗∗∗p < 0.005 significance levels. Microsoft
Excel, SPSS version 25 and GraphPad softwares were used for
statistical evaluation. Mean + SD or median and 25 percentile
values are shown with n = 3–5 biological replicates, unless
otherwise indicated.
RESULTS
Fibroblast Activation Does Not Modify
EV Release Intensity
Fibroblasts in tumors show a characteristic gene expression
profile and thus, these CAFs are considered to be in an activated
state. TGFβ is critically involved in colon fibroblast activation,
e.g., it induces the initial steps of metastasis formation by
inducing IL-11 secretion from fibroblasts (Calon et al., 2012).
To study the effects of EVs released by activated fibroblasts on
CRC cells, first we used a widely accepted and reproducible,
commercially available model system, normal human colon-
derived fibroblasts (NCF), and we activated them by TGFβ.
As previously published, TGFβ reduced the proportion of the
KI67+ proliferating cells (Calon et al., 2015) and increased the
intensity of αSMA expression, a general marker of intestinal
myofibroblasts (Figures 1A,B). Importantly, we found no
change in the percentage of active caspase-3+ apoptotic cells
(Figure 1C). As expected, we observed an increased RNA level
of FAP, ACTA2 (encoding αSMA), IL6, IL-11, and HBEGF, thus,
proving that TGFβ treatment led to characteristic transcriptional
changes (Figure 1D). Importantly, TGFβ resulted in larger
wound area in a wound healing assay (Figure 1E), showing the
reduced migration of NCFs.
Similarly to our previous results (Oszvald et al., 2020), EVs
were detected in NCF conditioned medium by transmission
electron microscopy (TEM; Figure 2A). In addition, we also
detected EVs in these samples when using anti-CD63 or anti-
CD81-coated beads and flow cytometry (Figures 2B,C). CD81
and CD63 are markers characteristic for EVs, thus, this bead-
based method collects EVs semi-quantitatively from cell culture
supernatants (Figure 2D; Ostrowski et al., 2010; Szvicsek et al.,
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FIGURE 1 | TGFβ activates normal colon fibroblasts (NCF). (A,B) KI67 and αSMA immunostaining of NCFs with or without TGFβ (4 days). Confocal microscopic
images (A) and their quantification (B). αSMA intensity was determined by ImageJ software. (C) The proportion of active caspase-3+ apoptotic control or
TGFβ-treated NCFs, based on immuncytochemistry, and confocal microscopic images. (D) mRNA fold change of the indicated genes in NCFs (RT-qPCR, n = 6,
paired samples). (E) Relative wound area compared to the initial area (right) and to the area of the untreated samples at each time point (left) in confluent fibroblast
cultures (n = 3, paired samples). Data were obtained from three repeated experiments in (B,C). Mann–Whitney U-test (B,C) or paired t-test (D,E) were used with
*p < 0.05, **p < 0.01, and ***p < 0.005. Scale bars: 50 µm (A).
2019). By using this method, we did not find an increased CD81+
or CD63 + EV release after TGFβ (Figure 2E). Similarly, NTA,
a widely used method for quantifying EV amounts, showed no
difference in particle concentration and no shift in particle size
distribution after treatment (Figures 2F–H). Importantly, all
these data have been normalized to cell number, excluding the
possibility that changes in the percentage of the proliferating
cells after TGFβ treatment could influence our conclusions. Thus,
these results indicate that TGFβ-induced NCF activation did not
have a major effect on EV secretion.
TGFβ-Induced Fibroblast Activation
Modifies the miRNA Cargo of EVs
To determine changes in the EV cargo after NCF activation, we
first focused on miRNAs that have a known important role in
EV-mediated intercellular communication. Previously we proved
that miRNAs from EVs isolated by antibody-coated beads had
less unspecific miRNA background compared to other methods.
Thus, we applied anti-CD63-coated and anti-CD81-coated beads
for our miRNA analysis (Szvicsek et al., 2019). The medium-scale
screen, analyzing 377 miRNAs, detected 209 miRNAs in at least
one of the six samples measured (Figure 3A and Supplementary
Table S5). Interestingly, we found that four miRNAs (hsa-miR-
101, 382, 424, and 642) were present only in TGFβ-treated EV
samples (Figure 3B and Supplementary Table S5). Thus, NCF
activation changes the miRNA profile of the EV cargo.
Fibroblast-Derived EVs Induce CRC Cell
Proliferation via Transporting AREG
Independently of TGFβ Activation
Normoxic fibroblast-derived EVs had no effect on the colony
formation of CRC organoid cells in the presence of EGF (Szvicsek
et al., 2019). In addition, we proved earlier that at least one of
the EGF family members, AREG, travels via fibroblast-derived
EVs (Oszvald et al., 2020). Thus, EVs may be important for
EGF-dependent organoids with wild type KRAS and BRAF in
the absence of external EGF family members, such as AREG.
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FIGURE 2 | TGFβ has no effect on EV release from normal colon fibroblasts (NCF). (A) Transmission electronmicroscopic (TEM) images of the UC pellet derived from
NCF supernatant. The arrows show EVs. (B,C) Detecting EVs from NCF supernatants with anti-CD81 or anti-CD63-coated beads. Flow cytometric images (B) and
quantification of the data (C). Serum-free medium (NCF-) samples were compared to NCF supernatants (NCF+; n = 3). (D) The percentage of anti-CD63 or
anti-CD81-coated positive beads after incubation in supernatants from NCF cultures with different cell numbers (flow cytometry, n = 4). (E) The percentage of
positive beads after incubating them in control or TGFβ-treated (10 ng/ml, 4 days) NCF supernatant (normalized to cell number). (F–H) Representative images (F),
the concentration of particles (G, normalized to 100,000 cells), and their mode size (H) in control and TGFβ-treated NCF supernatants (NTA). Mann–Whitney U-test
(E,G,H) or paired t-test (C) were used. Scale bars: 50 nm (A). ***p < 0.005.
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FIGURE 3 | TGFβ modifies the miRNA profile of NCF-derived fibroblasts. (A) The presence/absence of miRNAs in the untreated/treated NCF EV samples. Note that
only miRNAs that were present in at least one of the samples are shown. (B) miRNAs present in all TGFβ-treated samples and absent in all controls.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 7 July 2020 | Volume 8 | Article 558
fcell-08-00558 July 3, 2020 Time: 20:1 # 8
Oszvald et al. Extracellular Vesicles and Amphiregulin in Colorectal Cancer
FIGURE 4 | NCF-derived EVs induce the proliferation of CRC organoid cells via carrying AREG. (A,B) Representative confocal microscopic images (A) and the
quantification of KI67+ cells in CRC patient-derived organoid lines with the indicated treatments. Note that 2.5 × 107 NCF-derived EVs were applied. (C,D) Cell
number (C) and diameter (D) of CRC organoids Kruskal–Wallis and Dunn’s multiple comparison tests were used (B,C,D) with *p < 0.05, **p < 0.01, and
***p < 0.005. Scale bars: 100 µm (A). Confocal microscopic images were quantified from three experiments for each organoid line for (B–D).
We first added NCF-derived EVs to patient-derived organoid
lines known to be dependent on EGF [(Szvicsek et al., 2019)
and see section “Human colon organoid cultures”]. Importantly,
we observed a marked reduction in the percentage of KI67+
proliferating organoid cells in the absence of AREG which
was restored by NCF-derived EVs (Figures 4A,B). In addition,
blocking EGF receptor by the EGF receptor inhibitor gefitinib
or pre-incubating EVs with a neutralizing anti-AREG antibody
inhibited the effects of EVs (Figures 4B–D), thus, proving the
critical role of EV-bound AREG on CRC cell proliferation. In
addition, the proportion of active caspase-3+ apoptotic organoid
cells increased in the absence of AREG and this was restored
by control or TGFβ-treated NCF-derived EVs (Figure 5A).
Interestingly, we observed no difference in the percentage of
KI67 + cells when CRC organoids were treated with identical
numbers of EVs isolated from control or TGFβ-activated NCFs
(Figure 5B). Importantly, AREG was present on both control
and treated NCF-derived EVs, detected by latex beads that bind
EVs (Figure 5C). Thus, although TGFβ resulted in a change of
EV miRNA cargo, this had no effect on CRC cell proliferation
and both control and activated fibroblast-derived EVs induced
CRC proliferation via AREG in organoids that are dependent on
EGF family members.
EVs do Not Critically Modify the
Proliferation of EGF-Independent CRC
Cells
We next tested a 3D model system of CRC cells that are
independent of EGF activity. The SW1222 cells form 3D
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FIGURE 5 | TGFβ does not modify the effects of EVs either in EGF-dependent or in EGF-independent 3D models. (A) The percentage of active caspase-3+ cells in
CRC patient-derived organoid lines in the presence or absence of AREG, control, or TGFβ-treated NCF-derived EVs. (B) The effect of NCF-derived EVs on CRC
organoids. NCFs were pre-treated with TGFβ (TGFβ EV) or they were cultured untreated (Ctr EV) before collecting EVs. (C) Detecting AREG on EVs isolated from
control (Ctr EV) or TGFβ-treated NCFs (TGFβ EV) and bound to latex beads (flow cytometry). (D,E) The percentage of KI67+ cells in SW1222 cell-derived colonies in
the presence of the indicated treatments. Representative confocal microscopic images (D) and their quantification (E). EVs were isolated from control or
TGFβ-treated (4 days) NCF cultures. Kruskal–Wallis and Dunn’s multiple comparison tests were used (A,B,E). Confocal microscopic images were quantified from
three experiments for (A,B,E). Scale bars: 50 µm (D). *p < 0.05, **p < 0.01, ***p < 0.005.
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organoid-like structures and the larger megacolonies contain
lumens (Yeung et al., 2010, 2011). Importantly, the presence
and the number of lumens correlate with CRC stem cell activity
and differentiation. Furthermore, megacolonies highly resemble
organoids (Yeung et al., 2010), and these cells do not require EGF
family members. As expected, recombinant AREG had only a
marginal inducing effect on the proportion of KI67 + cells and
neither control nor TGFβ-activated NCF-derived EVs modified
the ratio of proliferating cells (Figures 5D,E). These data
suggest that EVs released by fibroblasts have no effect on CRC
proliferation when EGF activity is dispensible.
TGFβ Does Not Modify EV Release in
CRC Patient-Derived Fibroblasts
To prove our findings in another model system, we established
cultures from the peritumoral (normal) colon segment (PTF) and
the CRC tissue (CRC-F) of patients. Similarly to NCFs, TGFβ
reduced the proportion of the proliferating cells and increased
the intensity of αSMA expression, a general marker of intestinal
myofibroblasts, in both CRC-Fs and PTFs (Figures 6A,B).
Furthermore, we observed an increased RNA level of FAP,
ACTA2, IL-6, IL-11, and HBEGF (Figure 6C). Unlike NCFs,
TGFβ induced the appearance of IL-6 + cells both in PTF and
CRC-F cultures (Figures 6D,E), resulting in the heterogeneity
in fibroblast cultures. To further characterize the response of
the fibroblast cultures to TGFβ, we carried out wound healing
assay. Interestingly, we observed no difference in the wound
area after TGFβ treatment in either PTFs or CRC-F cultures
(Figure 6F). In addition, CRC-Fs showed a lower percentage of
cells positive for SA-β-galactosidase activity, a widely used marker
for senescence, compared to their paired PTFs (Figure 6G).
TGFβ had no effect on the precentage of senescent cells
in either fibroblast subpopulations (Figure 6H). Importantly,
TGFβ-induced fibroblast activation did not modify the amount
of secreted EVs either in PTFs or in CRC-Fs, as detected by
NTA, with anti-CD63 or anti-CD81-coated beads (Figures 7A–
D). Thus, we found that TGFβ induced similar changes both in
PTFs and in CRC-Fs.
CRC-F-Derived EVs Induce CRC
Proliferation in EGF-Dependent
Patient-Derived Organoid Lines
Since we found no difference between our PTF and CRC-F
cultures in their activation, we focused on CRC-F fibroblasts.
Similarly to NCFs, we detected AREG on both control and
TGFβ-treated CRC-F-derived EVs by flow cytometry (Figure 8A)
and these EVs restored the proportion of KI67 + CRC cells in
EGF-dependent organoids in the absence of exogenously added
EGF family members (Figures 8B,C). Importantly, we observed
no difference when CRC-F cultures had been pre-treated with
TGFβ and identical numbers of EVs were applied (Figures 8B,C).
Thus, our results show that fibroblast-derived EVs induce CRC
proliferation via an activation-independent mechanism only in
EGF-dependent CRC organoids.
DISCUSSION
In this study we prove that the TGFβ-induced activation
of NCFs modifies EV miRNA cargo and hsa-miR-101, 382,
424, and hsa-miR-642 are present only in EVs derived
from activated NCFs. In addition, TGFβ results in gene
expression changes in CRC-Fs as well. However, fibroblast-
derived EVs induced CRC cell proliferation of EGF-dependent
patient-derived organoids via carrying amphiregulin AREG,
independently of the TGFβ-induced EV cargo change and
fibroblast activation. In addition, EVs had no role in a 3D system
where EGF activity was not required.
Although stromal cells, such as fibroblasts, are critical in
the progression of many tumor types, their exact activation
mechanism and the role of fibroblast subpopulations is still
poorly known. As an example, pancreatic ductal adenocarcinoma
(PDAC), an extremely aggressive cancer with an accumulation
of stromal elements, contains myCAF and iCAF fibroblast cells
(Ohlund et al., 2017; Biffi et al., 2019). Whereas fibroblasts
with contact to tumor cells express αSMA and differentiate
to myCAFs, peripheral cells produce IL–6 as iCAFs (Ohlund
et al., 2017). In addition, TGFβ inhibits the differentiation to
iCAFs, thus, this cytokine plays a central role in shaping the
activation pattern of CAFs (Biffi et al., 2019). Interestingly, a
previous publication found that IL-6 + fibroblasts are present
in CRC as well (Huynh et al., 2016). In line with these
results, we provide evidence that TGFβ is critically involved
in establishing this fibroblast heterogeneity both in PTFs and
in CAFs. The importance of cellular heterogeneity has also
been proven in normal human colon fibroblasts by identifying
subpopulations with differential expression profile (Kinchen
et al., 2018). Interestingly, TGFβ did not result in the appearance
of IL-6 + fibroblasts in NCFs in our experiments, however,
other profile changes may have occured that we have not
tested in our work.
Peri-tumoral fibroblasts are often used as normal fibroblast
controls (Berdiel-Acer et al., 2014). However, a recent study
found only a limited amount of difference in gene expression
between PTFs and CRC-Fs and αSMA, generally considered as
a marker of activated fibroblasts, was present in PTFs as well
(Berdiel-Acer et al., 2014). Furthermore, TGFβ is considered as
a major inducer of fibroblast activation in CRC (Calon et al.,
2012), leading to the expression of characteristic genes, such as
IL-11 (Calon et al., 2012). Interestingly, both PTFs and CRC-Fs
produced more IL-11, ACTA2, HBEGF, IL-6, and FAP when they
were treated with TGFβ, suggesting that these cells can be further
activated in vitro. In our experiments, PTFs and CRC-Fs behaved
similarly in the tested parameters after TGFβ treatment, such as
cellular heterogeneity, gene expression changes, wound size in
wound healing assays or cell senescence. Thus, these results show
that either PTFs were already in a pre-activated state or CRC-Fs
lost their activated features in our system.
Not only CRC cell-derived EVs, but also EVs released
by stromal cells may be important in tumorigenesis.
Inhibiting ELFN1-AS1 long non-coding RNA in umbilical
cord mesenchymal stem cell-derived EVs suppresses colon
adenocarcinoma proliferation and migration in cell lines
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FIGURE 6 | TGFβ activates PTFs and CRC-Fs. (A,B) αSMA and KI67 immunostaining in control and TGFβ-treated (4 days) PTFs or CRC-Fs (confocal microscopy;
A) and their quantification (B). αSMA expression intensity was determined by the ImageJ software. (C) Fold change of the indicated mRNAs in TGFβ-treated
fibroblasts compared to untreated controls (RT-qPCR, n = 4). Note that pairwise comparisons were carried out between control and treated samples. (D) IL-6 and
αSMA detection in PTFs and CRC-Fs (confocal microscopy). (E) The proportion of IL-6+ cells with the indicated treatments (quantification of confocal microscopy
images). (F) Relative wound area of the TGFβ-treated fibroblasts compared to the control confluent fibroblast cultures (n = 3). (G–H) The proportion of cells with
SA-β-galactosidase activity. Representative microscopic images (G) and their quantification (G-H, n = 3, paired samples). Mann–Whitney U-test (B,E) or paired t-test
(C,F,G,H) were used with *p < 0.05, **p < 0.01, and ***p < 0.005. Scale bars: 50 µm (D,G).
(Dong et al., 2019). Furthermore, granulocytic myeloid-derived
suppressor cells release EVs that promote the stem cell-like
properties of CRC cells through S100A9 (Wang et al., 2019).
In addition, EVs secreted by macrophages polarized to the
M2 direction induce CRC cell migration (Lan et al., 2019).
Interestingly, in two elegant studies fibroblast-derived EVs have
been proven to promote resistance for chemotherapeutic drugs
in CRC (Hu et al., 2015; Hu J. L. et al., 2019) and by using
cell lines and xenografts, the authors found that the effect was
accomplished by dedifferentiation of CRC cells to cancer stem
cells via Wnt proteins (Hu Y. B. et al., 2019). Previously we found
that normoxic fibroblast-derived EVs did not affect the colony
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FIGURE 7 | TGFβ does not modify EV release from peritumoral (PTF) or tumor (CRC-F) fibroblasts. (A,B) The concentration (A, normalized to 100,000 cells) and
mode size of the particles (B) from PTF or CRC-F cells with or without pre-treatment with TGFβ (10 ng/ml, 4 days), measured by NTA. C,D) The percentage of
anti-CD63 (C) or anti-CD81-coated (D) positive beads (normalized to cell number, see section “Semi-quantitative analysis of EVs by anti-CD63 or anti-CD81-coated
beads”) that were incubated in supernatants from the indicated cells. Mann–Whitney U-test was used.
number of CRC organoids in the presence of EGF (Szvicsek et al.,
2019). In our present study we identified a novel mechanism how
fibroblast-derived EVs induce CRC tumorigenesis by carrying
AREG when EGF is absent from the culture medium. So far
all previously published works used cell lines and xenografts.
Importantly, we used patient-derived organoids in our studies
that is one of the best current models for human cancers by
maintaining the intra-patient tumor cell heterogeneity. Since
we selected CRC organoids for mutations in the Wnt pathway
by removing the Wnt agonist R-Spondin1 from organoid
culture medium, our surviving organoid lines did not require
external Wnt proteins, thus, the effect of EV-bound Wnt proteins
could not be studied in our system. CAF-derived EVs promote
metastasis and epithelial-mesenchymal transition (EMT) by
miR-92a-3p and this effect was more pronounced compared to
control fibroblasts (Hu J. L. et al., 2019). Interestingly, we found a
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FIGURE 8 | CRC-F cell-derived EVs increase the percentage of proliferating CRC organoid cells independently of pre-treatment with TGFβ. (A) Detecting AREG on
EVs isolated from control or TGFβ-treated CRC-F cells and bound to latex beads (flow cytometry). (B,C) The percentage of KI67+ CRC organoid cells with or without
AREG or EVs derived from control or treated CRC-Fs (paired fibroblast and organoid samples). Confocal microscopic images (B) and quantification (C).
Kruskal–Wallis and Dunn’s multiple comparison tests (C) were used. Scale bars: 50 µm. ***p < 0.005.
change in the EV cargo with miR-101, 382, 424, and 642 present
only in EVs released by TGFβ-treated activated fibroblasts. The
role of these miRNAs in CRC proliferation and apoptosis is
controversial. Whereas miR-101 has an anti-proliferative effect
(Sastre et al., 2019; Shao et al., 2019) the level of miR-382 is
elevated in CRC and it induces tumor progression (Savardashtaki
et al., 2019). Importantly, organoids are routinely cultured
in the laminin-rich 3D matrix Matrigel which is not suitable
to model invasion and metastasis. Thus, AREG transported
by EVs is critical in inducing cell proliferation in organoids
that are dependent on EGF activity, however, changes in the
miRNA EV cargo after fibroblast activation is not central in
inducing CRC proliferation and it may become important in
other steps of CRC tumorigenesis. Furthermore, in contrast to
the effect of miR-92a-3p (Hu J. L. et al., 2019), we found no
difference in CRC cell proliferation or apoptosis when using
normal fibroblasts, CRC-Fs or when these cells were pre-treated
with TGFβ, suggesting that the AREG-mediated EV effect is
independent of fibroblast activation.
The EGF ligand family members are synthesized as
membrane-bound molecules and they are cleaved by proteases
to result in soluble molecules. However, many EGF family
members, such as AREG may act in its membrane-bound
uncleaved form in a juxtacrine manner as well (Singh and
Harris, 2005; Berasain and Avila, 2014). Indeed, several studies
have identified unprocessed AREG on EVs and proved its
EV-bound activity (Higginbotham et al., 2011; Taverna et al.,
2017; Raimondo et al., 2019; Zhang et al., 2019). We previously
published that AREG transported by fibroblast-derived EVs
plays an important role in shaping the intestinal stem cell niche
by providing EGF activity (Oszvald et al., 2020). Importantly,
EVs can be taken up into the target cells with endocytosis or
macropinocytosis and this process is induced by EGF receptor
activation (Nakase et al., 2015). In addition, activated EGF
receptor is internalized with the EGF ligand and they continue
stimulating signaling pathways even after endocytosis (Tomas
et al., 2014). Thus, this raises the possibility that EVs induce
CRC cell proliferation via cell surface binding between AREG
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and EGF receptor, and/or after endocytosis. Although further
studies will be needed to decide the exact mechanism, we
provide here evidence that EV-bound AREG critically induces
CRC cell proliferation when CRC cells have an unmutated EGF
signaling pathway.
Collectively, by using the 3D organoid model, we show that
fibroblast-derived EVs transport AREG and they increase the
number of proliferating CRC cells in patient-derived organoid
lines that are dependent on external EGF activity, but not in
an EGF-independent model system. Although NCFs activated
by TGFβ secrete EVs with a characteristic difference in their
miRNA content compared to controls, we found no difference
in the effect of EVs when NCFs were pre-activated by TGFβ.
Similarly, EVs from CRC-Fs pre-activated by TGFβ did not
modify the proportion of proliferating CRC organoid cells. All
these data point to the critical and activation-independent role
of AREG transported by fibroblast-derived EVs at early stages
of CRC tumorigenesis when the EGF signaling pathway is
not yet mutated.
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